Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2025-6079

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

Autologous, allogeneic haemopoietic stem cell transplantation and CART cell therapy for tranformed Waldenström's macroglobulinemia to high grade non-Hodgkin lymphoma. real world outcomes report from the lymphoma working party of the european society for blood and marrow transplantation (LWP EBMT)

Charalampia Kyriakou, Maud NGOYA, Nour Moukalled, Irma Khvedelidze, Silvia Montoto, Luca Castagna, Didier Blaise, Lauris Gastaud, Robert Zeiser, Marek Trneny, Malte Von Bonin, Herve Ghesquieres, Koen Debackere, Matthias Stelljes, Olivier Tournilhac, Ali Bazarbachi

Blood (2025) 146 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2025-3718

Published: 2025

Journal Articles

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2025-4279

Published: 2025

Journal Articles

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Blood (2025) 146 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2025-4284

Published: 2025

Journal Articles

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Blood (2024) 144 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2024-197901

Published: 2024

Journal Articles

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2024-206733

Published: 2024

Journal Articles

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 896.

https://doi.org/10.1182/blood-2023-179489

Published: 2023

Journal Articles

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Nour Moukalled, Myriam Labopin, Jurjen Versluis, Gerard Socié, Didier Blaise, Urpu Salmenniemi, Alessandro Rambaldi, Tobias Gedde-Dahl, Eleni Tholouli, Nicolaus Kröger, Jean-Henri Bourhis, Peter A. Von Dem Borne, Etienne Daguindau, Édouard Forcade, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2023-185434

Published: 2023

Journal Articles

The Impact of Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes in Patients Diagnosed with Acute Myeloid Leukemia and Persistent Measurable Residual Disease: A Retrospective Cohort

Racha Khodr, Ammar Zaherddine, Maya Charafeddine, Nour Moukalled, Jean El-Cheikh, Ali Bazarbachi, Iman Abou Dalle

Blood (2022) 140 (Supplement 1): 12904–12905.

https://doi.org/10.1182/blood-2022-169237

Published: 2022

Journal Articles

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Nour Moukalled, MD, Radwan Massoud, BS, MD, Rami Mahfouz, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2018) 132 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2018-99-118893

Published: 2018

Journal Articles

Safety and Efficacy of Thiotepa Based Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Single Center Experience

Jean Elcheikh, MD, Radwan Massoud, MD, Nour Moukalled, Basel Haffar, MD, Ammar Zaherddine, RN, Charafeddine Maya, Rami Mahfouz, MD, Ali Bazarbachi, MD PhD

Blood (2017) 130 (Supplement 1): 5473.

https://doi.org/10.1182/blood.V130.Suppl_1.5473.5473

Published: 2017

Journal Articles

Interim Disease Evaluation Post Induction Chemotherapy for Acute Myeloid Leukemia

Nour Moukalled, Radwan Massoud, MD, Rami Mahfouz, MD, Zaher Chakhachiro, MD, Samer Nassif, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2017) 130 (Supplement 1): 5022.

https://doi.org/10.1182/blood.V130.Suppl_1.5022.5022

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Autologous, allogeneic haemopoietic stem cell transplantation and CART cell therapy for tranformed Waldenström's macroglobulinemia to high grade non-Hodgkin lymphoma. real world outcomes report from the lymphoma working party of the european society for blood and marrow transplantation (LWP EBMT)

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD

Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

The Impact of Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation on Survival Outcomes in Patients Diagnosed with Acute Myeloid Leukemia and Persistent Measurable Residual Disease: A Retrospective Cohort

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Safety and Efficacy of Thiotepa Based Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Single Center Experience

Interim Disease Evaluation Post Induction Chemotherapy for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only